Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods.

Differences in scoring methods for estrogen receptor (ER) immunohistochemistry may cause significant variation in the results. Scoring practices differ within the United States and internationally and include semiquantitative scoring formulas, manual estimations, and computer-assisted techniques. The goal of this study was to determine the rate of interobserver variability for manual ER scoring at our institution and compare the ER scores obtained by manual scoring with those obtained using image-analysis software (QCA, Lake Bluff, IL). In a series of 70 consecutive invasive breast cancers, ER was assayed using standard immunohistochemical techniques and the monoclonal antibody 6F11. Scoring was performed independently by three breast pathologists, and the scores were compared with those obtained using the QCA image-analysis system, using 10% nuclear staining as the cutoff for positivity. We found that 43 cases (61%) were ER positive, 25 cases (36%) were ER negative, and two cases (3%) showed ER staining of less than 10%. The consensus scores for the 70 cases showed a high level of agreement with the ER scores determined by image analysis (kappa = 0.84). Interobserver variability was low. The kappa scores for each observer showed strong agreement with the consensus score, the image-analysis score, and between the observers. Our findings show that interobserver agreement for manual scoring of ER is strong, and that manual or computer-aided scoring techniques are comparable.

[1]  B. Fisher,et al.  Tamoxifen with and without radiation after partial mastectomy in patients with involved nodes. , 1995, International journal of radiation oncology, biology, physics.

[2]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. , 1995, Journal of the National Cancer Institute.

[3]  P. Bendahl,et al.  Estrogen and Progesterone Receptor Assay in Paraffin-Embedded Breast Cancer , 2003, Acta oncologica.

[4]  L. Layfield,et al.  Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. , 1998, American journal of clinical pathology.

[5]  B. Fisher,et al.  Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence. , 1998, International journal of radiation oncology, biology, physics.

[6]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[7]  L. Layfield,et al.  Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early‐stage breast carcinomas: Prognostic significance , 1996, Journal of surgical oncology.

[8]  F Breitenecker,et al.  Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison. , 1999, Anticancer research.

[9]  B. Angus,et al.  New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry , 1997, The Journal of pathology.

[10]  W. Bezwoda,et al.  The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen , 1991, Cancer.

[11]  S. Bacus,et al.  Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[12]  J. Jacquemier,et al.  Estrogen receptor immunocytochemical assay (ER-ICA): computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas. , 1986, Cancer research.

[13]  J M Esteban,et al.  Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. , 1994, Journal of cellular biochemistry. Supplement.

[14]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[15]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Layfield,et al.  Assessment of Tissue Estrogen and Progesterone Receptor Levels: A Survey of Current Practice, Techniques, and Quantitation Methods , 2000, The breast journal.

[17]  R. Gelber,et al.  Meeting highlights: international consensus panel on the treatment of primary breast cancer. , 2002, Journal of the National Cancer Institute.

[18]  H. Frierson,et al.  Automated immunohistochemical assay for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on the Ventana ES. , 1996, American journal of clinical pathology.

[19]  J. Feldman,et al.  Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol‐based ligand‐binding assays , 1996, Cancer.

[20]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Duffy,et al.  Objective measurement of breast cancer oestrogen receptor status through digital image analysis. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  S. Swain Tamoxifen for patients with estrogen receptor-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.